Scarica l'app Stockscreener
1.76
4.37%
-0.07
Acrivon Therapeutics Inc Borsa (ACRV) Ultime notizie
Is Acrivon Therapeutics Inc. still worth holding after the dipIndex Update & Fast Momentum Entry Tips - newser.com
News impact scoring models applied to Acrivon Therapeutics Inc.July 2025 Trade Ideas & Fast Exit and Entry Strategy Plans - newser.com
How Acrivon Therapeutics Inc. stock valuations compare to rivalsMarket Performance Recap & Daily Technical Stock Forecast Reports - newser.com
What Fibonacci levels say about Acrivon Therapeutics Inc. reboundPortfolio Value Report & Fast Moving Stock Trade Plans - newser.com
Is Acrivon Therapeutics Inc. stock positioned well for digital economyPortfolio Gains Summary & Safe Entry Momentum Stock Tips - newser.com
Acrivon Therapeutics (NASDAQ:ACRV) Given "Sell (E+)" Rating at Weiss Ratings - MarketBeat
Sector ETF performance correlation with Acrivon Therapeutics Inc.July 2025 PreEarnings & Long-Term Investment Growth Plans - newser.com
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates - 富途牛牛
Risk vs reward if holding onto Acrivon Therapeutics Inc.July 2025 Market Mood & Safe Entry Trade Reports - newser.com
Will Acrivon Therapeutics Inc. stock benefit from sector rotationInflation Watch & Fast Entry Momentum Alerts - newser.com
What to expect from Acrivon Therapeutics Inc. in the next 30 daysJuly 2025 Highlights & High Accuracy Investment Entry Signals - newser.com
Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Rises By 127.8% - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 127.8% in September - MarketBeat
Spotlight On 3 Promising Penny Stocks With Over $50M Market Cap - simplywall.st
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
225,000 Stock Options: Biotech Acrivon Therapeutics Awards Major Inducement Grant to Key New Hire - Stock Titan
Acrivon Therapeutics, Inc. $ACRV Holdings Decreased by Goldman Sachs Group Inc. - Defense World
Brokerages Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Target Price at $15.00 - Defense World
Tools to assess Acrivon Therapeutics Inc.’s risk profileTreasury Yields & Stepwise Trade Signal Guides - newser.com
0.21%
2.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):